In acute lymphoblastic leukemia (ALL), steroid resistance and hypovitaminosis D are both associated with a poor prognosis. We show that methylprednisolone, calcitriol and the AKT-inhibitor MK-2206 have a synergistic effect on the apoptosis of steroid resistant T-ALL cells. Compared to methylprednisolone monotherapy, calcitriol increases methylprednisolone induced apoptosis dose-dependently (1.37-1.92-fold; p < 0.05). Pre-incubation with calcitriol increases the apoptotic effect of MK-2206 even further (3.6-fold; p < 0.05). It also potentiates synergism between MK-2206 and methylprednisolone (vehicle control 38% vs. calcitriol 58%, p < 0.01). The combination of calcitriol and AKT inhibition should be investigated further as treatment options for steroid resistance in T-ALL.
Introduction
Glucocorticoids (GC) are a core component of current treatment protocols in T-cell acute lymphoblastic leukemia (T-ALL) and act mainly through the induction of apoptosis [1] . Nevertheless, GC-resistance is common in T-ALL, which negatively impacts the overall prognosis [2, 3] . In addition to GC-resistance, also hypovitaminosis D appears to be associated with a decreased treatment response and a reduced prognosis in patients with hematological malignancies [4] . More than 70% of children with ALL have subnormal levels of 1,25-OH 2 vitamin D 3 (calcitriol), which is the active form of vitamin D [5] . Using primary human T-cells, we recently demonstrated that 1,25-OH 2 vitamin D 3 upregulates the GC receptor and increases GC induced apoptosis [6] . In this study, we aimed to investigate whether there is a synergistic action of calcitriol on GC-induced apoptosis of a steroid resistant T-ALL cell line (Jurkat). Since steroid resistance is also associated with defective IL-7 signaling trough JAK/STAT, PI3K/AKT and MEK [7] , we furthermore investigated inhibitors of AKT (MK-2206), JAK 1/2 (ruxolitinib) and MEK (CI-1040) for possible additional synergisms between GC and calcitriol.
Methods
Jurkat cells (Clone: E 6-1, kindly provided by the Department of Virology, University of Bochum, Germany; 1 ×10 7 cells/ml) were cultured in RPMI 1640 (Invitrogen, Carlsbad, USA), 1% penicillin/streptomycin (Invitrogen), 300 mg/l L-Glutamine (Invitrogen) with 10% FCS (Sigma-Aldrich, St. Louis, USA) at stable ambient conditions (37°C/5% CO 2 ). First, cells were treated with calcitriol (100 nM, 1 µM; Medchem Express, Monmouth Junction, USA) dissolved in DMSO (final DMSO 
Results
We first investigated whether calcitriol induces apoptosis in Jurkat cells. Calcitriol treatment with up to 1 µM over 24 h did not induce apoptosis in Jurkat cells (1 µM: 6.1% and 100 nM: 6.3% vs. control: 5.9%, each p > 0.05). In contrast, MP concentrations above 0.63 mM significantly increased Jurkat cell apoptosis after 24 h (Table 1) compared to the untreated control condition. To evaluate a possible synergism, Jurkat cells were co-incubated with MP (2.5 mM) and calcitriol (100 nM; 1 µM). This dual therapy resulted in a calcitriol dosedependent 1.37-1.92-fold increase of cell death ( Fig. 1 A and B) . This effect was not specific for MP since calcitriol also increased dexamethasone (800 µM, 1000 µM) induced apoptosis by 1.51-1.58 fold synergistically with calcitriol (1 µM, p < 0.05; Supplementary Fig. 1 ).
Subsequently, we investigated whether the inhibition of signaling pathways involved in steroid resistance in T-ALL and treatment with MP/calcitriol have synergistic effects on the induction of apoptosis. Jurkat cells were pre-incubated with calcitriol (100 nM) or vehicle control for 24 h. They were subsequently treated with the respective control, MP, the MEK inhibitor CI-1040, the JAK 1/2 inhibitor ruxolitinib and the AKT inhibitor MK-2206 or a combination thereof.
First, CI-1040 failed to demonstrate additional effects on GC apoptosis irrespective of calcitriol supplementation (data not shown). In contrast, the JAK 1/2 inhibitor ruxolitinib showed synergistic effects with MP. However, this effect could not be increased by calcitriol preincubation ( Fig. 2A) . The inhibition of the AKT signaling pathway using MK-2206 also demonstrated a synergistic effect with MP, which further increased through calcitriol pre-incubation (Fig. 2B) . Interestingly, also a synergism between calcitriol and inhibition of the AKT pathway was found, which exceeded synergistic effects of MK-2206 and MP (Fig. 2B ).
Discussion
In our study, we demonstrated that the observed synergism of calcitriol and GC in primary human T-cells [6] can be transferred to a model of T-ALL. This is an intriguing finding as it connects two important observations in ALL patients: (I) a reduced overall prognosis of patients with a poor response to steroids and (II) the deficiency of serum vitamin D 3 , especially of serum 1,25-OH 2 vitamin D 3 [3, 5] . We additionally investigated to what extent calcitriol acts synergistically with the inhibitors of JAK 1/2, AKT and MEK pathways, which are also relevant for steroid resistance in T-ALL [7] . We identified a synergistic action of calcitriol with the AKT inhibitor MK-2206 alone as well as in combination with MP. Several vitamin D analogs have already shown the ability to inhibit AKT. Therefore, the treatment with MK-2206 and calcitriol could lead to a dual AKT inhibition, which might explain our finding [8] . The presented study bears several weaknesses and should only be interpreted as a pilot investigation. 1,25-OH 2 D 3 /MP concentrations used in our in vitro analysis are higher than achieved in therapeutic situations. Additionally, conflicting evidence exists concerning the effects of 1,25-OH 2 vitamin D 3 on dexamethasone efficacy in several pre-B ALL cell lines [9] . Nevertheless, our study clearly argues for additional research to investigate the effect of calcitriol on the therapeutic efficacy of glucocorticoids and AKT-inhibition in T-ALL patients and might have clinical implications for steroid resistant T-ALL.
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